Stockholders approve conversion of Series A Preferred Stock for up to $25M financing

Alzamend Neuro, Inc.

Proposal approved with 5,356,845 votes for, 79,371 against, 3,043 abstentions; no broker non-votes.
Conversion relates to Securities Purchase Agreement dated May 8, 2024, for total purchase price up to $25,000,000.
Approval required under Nasdaq Rule 5635 for issuance exceeding certain share thresholds.
Special meeting held July 8, 2024; record date May 29, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.